Codexis, Inc.
200 Penobscot DrIve
Redwood City, CA 94063
United States
Tel: 650-421-8100
Website: http://www.codexis.com/
About Codexis, Inc.
Since 2002, Codexis' works every day to unlock the power of proteins®!
Our vision for the future
We discover and develop more effective therapeutics, enable healthier choices, innovate sustainable processes and products, and reduce waste – all to create a brighter future. This unified vision is what drives Codexis to continually set high standards and raise expectations of what is possible and its impact on the world and communities around us.
Creating a sustainable world
Enabling sustainable processes and products is our priority towards reducing waste, pollution, and consumption. Enzymes, nature’s biocatalysts for millions of years, are significantly more safe for the environment than are chemicals. We engineer high-performance enzymes to enable industrial bioprocesses that address productivity needs without sacrificing the health of our planet.
Commitment to human health
We are committed to effective biological therapeutics and accurate health monitoring tools. Annually, Codexis participates in global Rare Disease Day and also hosts its own event, welcoming guests and patient support groups with onsite activities. Whether it is for novel pharmaceuticals, protein therapies, gene therapies, biosensors, or upstream research and development, our work – evolved enzymes – makes an impact on someone’s life daily. This is why we at Codexis continue to work harder and smarter; we believe every breath and every heartbeat matters.
Commitment to community
As a socially responsible company, Codexis strives to play a positive role by fostering a culture that promotes employee volunteering to support the communities where we operate. We participate in multiple initiatives throughout the year supporting local charitable organizations, Family Giving Tree, and Second Harvest Food Bank. To promote youth education, Codexis sponsors Future Protein Engineers, an online program encouraging innovation and creativity while having fun learning about science.
Are you ready to join our mission to fight rare diseases? Are you interested in enhancing protein optimization and production? Do you have a passion to help people have better quality of life? Come be part of the Codexis, Inc. team where every day we get to unlock the power of proteins®!
Codexis uses our world-leading CodeEvolver® protein engineering platform to discover novel therapies for the treatment of genetic disorders and other debilitating disease and to develop custom enzymes for a wide range of applications. We engineer proteins with high efficacy and safety with the goal of delivering the therapeutic to patients as an enzyme replacement, mRNA, or gene therapy.
But we can't do it without YOU!
We are rapidly growing, and we are presently seeking to expand our pipeline and diversify applications of our technology platform. We have a number of opportunities for passionate scientists that want to do something
71 articles with Codexis, Inc.
-
Codexis Announces New Employment Inducement Grants - March 09, 2023
3/9/2023
Codexis, Inc., a leading enzyme engineering company, announced the approval of equity grants to two new employees as approved by the Compensation Committee of Codexis’s Board of Directors.
-
Codexis to Participate in Cowen 43rd Annual Health Care Conference
2/27/2023
Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company, today announced that management will participate in both a panel discussion and a fireside chat at the Cowen 43rd Annual Health Care Conference, being held March 6-8, 2023, in Boston, Massachusetts.
-
Codexis Reports Fourth Quarter and Fiscal Year 2022 Financial Results
2/23/2023
Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced financial results for the fourth quarter and fiscal year ended December 31, 2022.
-
Codexis and Nestlé Health Science Announce Interim Results from Phase 1 Clinical Trial of CDX-7108 for Exocrine Pancreatic Insufficiency
2/23/2023
Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, and Nestlé Health Science, a leader in the science of nutrition, today announced interim results from a Phase 1 study to investigate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of CDX-7108.
-
Codexis Announces Several Key Presentations from its Gene Therapy Programs at 19th Annual WORLDSymposium™
2/22/2023
Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today highlights several key presentations from its gene therapy programs from 19th Annual WORLDSymposium™, taking place from February 22-26, 2023, in Orlando, Florida.
-
Codexis Announces New Employment Inducement Grants - February 15, 2023
2/15/2023
Codexis, Inc., a leading enzyme engineering company, announced the grant of an inducement award to the Company’s recently appointed Chief Financial Officer, Sri Ryali.
-
Codexis to Report Fourth Quarter and Fiscal Year 2022 Financial Results on February 23
2/9/2023
Codexis, Inc., a leading enzyme engineering company, announced that it will report its financial results for the fourth quarter and fiscal year 2022 on Thursday, February 23, 2023, following the close of market.
-
Codexis Announces Appointment of Sri Ryali as Chief Financial Officer
1/23/2023
Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the appointment of Sri Ryali as Chief Financial Officer effective immediately.
-
Codexis Announces Appointment of H. Stewart Parker to Board of Directors
12/20/2022
Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the appointment of H. Stewart Parker to its Board of Directors.
-
Codexis Provides Update on Prioritized Corporate Strategy
11/29/2022
Codexis, Inc., a leading enzyme engineering company, announced an update on the Company’s ongoing plan to prioritize its time and resources on areas where the Company believes it has the strongest commercial opportunity and greatest probability of success.
-
Codexis to Participate in Piper Sandler 34th Annual Healthcare Conference
11/16/2022
Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that management will participate in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference, being held on November 29-December 1, 2022, in New York, New York.
-
Codexis to Participate in Upcoming Healthcare Conferences in November 2022
11/8/2022
Codexis, Inc., a leading enzyme engineering company enabling the promise of synthetic biology, announced that management will participate in three upcoming investor conferences.
-
The executive shuffle continues across the biopharma industry as companies shore up leadership needs with these Movers & Shakers.
-
Codexis Reports Third Quarter 2022 Financial Results
11/3/2022
Codexis, Inc., a leading enzyme engineering company enabling the promise of synthetic biology, announced financial results for the third quarter ended September 30, 2022 and provided a business update.
-
Codexis Announces Appointment of Margaret Fitzgerald as Chief Legal Officer and General Counsel
11/1/2022
Codexis, Inc., a leading enzyme engineering company enabling the promise of synthetic biology, announced the appointment of Margaret Fitzgerald as Chief Legal Officer and General Counsel, effective immediately.
-
Codexis to Report Third Quarter 2022 Financial Results on November 3
10/20/2022
Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that it will report its financial results for the third quarter of 2022 on Thursday, November 3, 2022, following the close of market.
-
Codexis Announces Appointment of Rahul Singhvi, Sc.D., to Board of Directors
10/3/2022
Codexis, Inc. today announced the appointment of Rahul Singhvi, Sc.D., to its Board of Directors.
-
Codexis Announces Appointment of Kevin Norrett as Chief Operating Officer
10/3/2022
Codexis, Inc. today announced the appointment of Kevin Norrett as Chief Operating Officer (COO), effective immediately.
-
Codexis’ 2022 Protein Engineering Forum Showcases Recent Industry Success and Emerging Innovations in the Field
9/14/2022
Codexis, Inc., a leading enzyme engineering company enabling the promise of synthetic biology, announced the recent hosting of its in-person Protein Engineering Forum from September 12-13, 2022 in San Francisco, California.
-
Codexis Reports Second Quarter 2022 Financial Results
8/4/2022
Codexis, Inc., a leading enzyme engineering company enabling the promise of synthetic biology, announced financial results for the second quarter ended June 30, 2022 and provided a business update.